REG - IXICO plc - Capital Markets Day Presentation and Video

IXICOAnnouncement

03/11/2025 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251103:nRSC9690Fa&default-theme=true

RNS Number : 9690F  IXICO plc  03 November 2025

IXICO plc

("IXICO", the "Company" or the "Group")

 

Capital Markets Day Presentation and Video

 

 

03 November 2025 IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, announces that a
recording of the Capital Markets Day held on Thursday 30 October 2025 is now
available on the Company's website.

 

To view the recording and a copy of the presentation, please the see the
Investors section of IXICO's website
https://ixico.com/investors/company-information/
(https://ixico.com/investors/company-information/)

 

 

Bram Goorden, CEO of IXICO, said: "As we presented during the Capital
Markets Day, IXICO are well on track to continue delivering double digit
topline growth and achieve profitability in the medium term. The future
success of IXICO will be defined by the continued evolution and innovation of
its AI-tech platform, and partnering this platform with the leading biopharma,
data and AI players in the field of neurological precision medicine".

 

Ends

 

For further information please contact:

 IXICO plc                                   +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited           +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUOASRVWUARAA



            Copyright 2019 Regulatory News Service, all rights reserved